Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cipla
Argus Health
Farmers Insurance
Chinese Patent Office
US Army
Dow
Covington
McKinsey

Generated: August 14, 2018

DrugPatentWatch Database Preview

Celator Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for CELATOR PHARMS, and what generic alternatives to CELATOR PHARMS drugs are available?

CELATOR PHARMS has one approved drug.

There are six US patents protecting CELATOR PHARMS drugs.

There are eighty patent family members on CELATOR PHARMS drugs in sixteen countries.

Summary for Celator Pharms
International Patents:80
US Patents:6
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Celator Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;IV (INFUSION) 209401-001 Aug 3, 2017 RX Yes Yes 8,022,279 ➤ Sign Up Y ➤ Sign Up
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;IV (INFUSION) 209401-001 Aug 3, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;IV (INFUSION) 209401-001 Aug 3, 2017 RX Yes Yes 8,092,828 ➤ Sign Up ➤ Sign Up
Celator Pharms VYXEOS cytarabine; daunorubicin POWDER;IV (INFUSION) 209401-001 Aug 3, 2017 RX Yes Yes 9,271,931 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Celator Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,238,367 Liposome loading with metal ions ➤ Sign Up
7,744,921 Liposome loading with metal ions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Johnson and Johnson
Cerilliant
Accenture
Mallinckrodt
McKesson
Citi
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.